Alphavirus Epitope Megapools for T Cell Response Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for optimized compositions and methods to detect and characterize Chikungunya virus-specific responses in infection and following vaccination, particularly for identifying antigens and T cell epitopes for diagnostics, treatments, and vaccines.
Innovation Solution
Compositions comprising peptides or proteins with specific amino acid sequences, including Alphavirus and Chikungunya virus T cell epitopes, formulated with adjuvants and immune modulators, are used for detecting immune responses and administering treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If a comprehensive panel of alphavirus T cell epitopes is used for detection, then the ability to detect and characterize Chikungunya virus-specific responses is improved, but the complexity of the detection system increases
Solution Approach 1:
The comprehensive epitope panel is segmented into multiple pools (e.g., Pool 1, Pool 2, Pool 3) containing specific subsets of epitopes. This allows the detection system to manage complexity through modular organization while maintaining comprehensive coverage. Each pool can be tested independently or in combination, providing flexibility in the detection protocol.
Solution Approach 2:
The epitope pools are designed to serve multiple functions: detecting Chikungunya virus-specific T cell responses, characterizing immune responses, and identifying viral epitopes. The same pool structure can be applied across different alphaviruses, providing universal applicability while maintaining virus-specific detection capability.
2Measurement precision
If multiple peptide pools are synthesized and tested, then the characterization of T cell responses is improved, but the time required for analysis increases
Solution Approach 1:
Epitope pools are pre-synthesized and pre-organized before actual detection experiments. This preliminary preparation allows for rapid deployment in detection assays without time-consuming synthesis during the analysis phase. The pools can be prepared in advance with known compositions, enabling quick start-up of detection protocols.
Solution Approach 2:
By dividing the comprehensive epitope set into multiple manageable pools, the analysis time is reduced compared to testing all epitopes individually. The segmented structure allows parallel testing of different pools and enables strategic selection of pools based on suspected viral proteins or immunodominant regions, optimizing the detection workflow.
3Reliability
If adjuvants and immune modulators are added to compositions, then the immunogenicity and T cell response are enhanced, but the formulation complexity increases
Solution Approach 1:
The patent explores different adjuvant types, concentrations, and combinations to optimize the immunogenicity of epitope compositions. By systematically varying formulation parameters (adjuvant type, dose, delivery method), the system achieves enhanced T cell responses while managing formulation complexity through data-driven optimization.
Solution Approach 2:
Adjuvants and immune modulators serve as intermediary substances that bridge the epitope antigens and the immune system. These intermediaries enhance the recognition and response to epitopes without being the primary antigenic target. The formulation complexity is managed by selecting adjuvants that provide robust immune enhancement with manageable safety and formulation requirements.
Data Source
AI summary
The present invention includes compositions, including epitope megapools, and methods for detecting the presence of: an Alphavirus or an immune response relevant to an Alphavirus infection including T cells responsive to one or more Alphavirus peptides or proteins comprising, consisting of, or consisting essentially of: one or more amino acid sequences selected from any sequence set forth in Table 1 (SEQ ID NOS: 1 to 150), or a subsequence, portion, homologue, variant or derivative thereof; a fusion protein; a pool of 2 or more peptides; a polynucleotide that encodes one or more peptides or proteins. The invention further provides vaccines, diagnostics, therapies, and kits, comprising such proteins or peptides.